Obesity, innate immunity and gut inflammation

Current Opinion in Gastroenterology

Volumn 23, Issue 6, 2007, Pages 661-666

  Karagiannides, Iordanes ^a   Pothoulakis, Charalabos ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adipocyte; Angiogenesis; IBD; Inflammation

Indexed keywords

ADIPOCYTOKINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLONY STIMULATING FACTOR; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; NEUROKININ 1 RECEPTOR; NEUROPEPTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; BACTERIUM; COMMENSAL; CROHN DISEASE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; ENTERITIS; HUMAN; HYPERLIPIDEMIA; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; NEOVASCULARIZATION (PATHOLOGY); OBESITY; PATHOPHYSIOLOGY; PROADIPOCYTE; REVIEW;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; INTESTINAL MUCOSA; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPEPTIDES; NF-KAPPA B; OBESITY; TOLL-LIKE RECEPTORS;

EID: 34848829522     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282c8c8d3     Document Type: Review

References (63)

1. Andoh A, Fujiyama Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J Gastroenterol 2006; 12:4452-4460.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
3. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999; 11:648-656.
4. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70:845-857.
5. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299Gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53:987-992.
6. Fortuno A, Rodriguez A, Gomez-Ambrosi J, et al. Adipose tissue as an endocrine organ: role of leptin and adiponectin in the pathogenesis of cardiovascular diseases. J Physiol Biochem 2003; 59:51-60.
7. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145:2273-2282.
8. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11:327-332.
9. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144:2195-2200.
10. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147:173-180.
11. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2:800-803.
12. Bruun JM, Verdich C, Toubro S, et al. Association between measures of insulin sensitivity and circulating levels of interleukin-8, interleukin-6 and tumor necrosis factor-alpha. Effect of weight loss in obese men. Eur J Endocrinol 2003; 148:535-542.
13. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117:73-81.
14. Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:100-105.
15. Charriere G, Cousin B, Arnaud E, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003; 278:9850-9855.
16. Levine JA, Jensen MD, Eberhardt NL, O'Brien T. Adipocyte macrophage colony-stimulating factor is a mediator of adipose tissue growth. J Clin Invest 1998; 101:1557-1564.
17. Lehrke M, Lazar MA. Inflamed about obesity. Nat Med 2004; 10:126-127.
18. Nieman DC, Henson DA, Nehlsen-Cannarella SL, et al. Influence of obesity on immune function. J Am Diet Assoc 1999; 99:294-299.
19. Ghanim H, Aljada A, Hofmeyer D, et al. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110:1564-1571.
20. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10:416-421.
21. Fontana L, Eagon JC, Trujillo ME, et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56:1010-1013. Analysis of blood samples of excessively obese patients demonstrated the direct participation of visceral fat in obesity-associated systemic inflammation. The study showed that mesenteric fat is responsible for the increased serum levels of at least IL-6.
22. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95:2111-2119.
23. Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2006; 92:1023-1033.
24. Vasudevan AR, Wu H, Xydakis AM, et al. Eotaxin and obesity. J Clin Endocrinol Metab 2006; 91:256-261.
25. Gerhardt CC, Romero IA, Cancello R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol 2001; 175:81-92.
26. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
27. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112:1821-1830.
28. Dandona P, Weinstock R, Thusu K, et al. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83:2907-2910.
29. Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-1804.
30. Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab 2004; 89:2608-2615.
31. Yesilbursa D, Serdar A, Heper Y, et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol 2005; 60:265-269.
32. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care 2004; 27:1699-1705.
33. Fried SK, Kral JG. Adipose tissue of morbidly obese patients: clinical implications of distribution, morphology, and metabolism. Gastroenterol Clin North Am 1987; 16:207-213.
34. Siegmund B, Lehr HA, Fantuzzi G. Leptin: a pivotal mediator of intestinal inflammation in mice. Gastroenterology 2002; 122:2011-2025.
35. Siegmund B, Sennello JA, Jones-Carson J, et al. Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice. Gut 2004; 53:965-972.
36. Sennello JA, Fayad R, Pini M, et al. Transplantation of wild type white adipose tissue normalizes metabolic, immune and inflammatory alterations in leptindeficient ob/ob mice. Cytokine 2007; 36:261-266. This well designed study associated adipose tissue-derived leptin to the generation of intestinal inflammation in ob/ob mice. The investigators performed transplantation of white adipose tissue from wild-type mice into ob/ob mice and showed normalization of otherwise impaired inflammatory responses and restoration of the susceptibility of these animals to DSS-induced colitis.
37. Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13:279-284.
38. Yamaguchi N, Argueta JG, Masuhiro Y, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005; 579:6821-6826.
39. Neumeier M, Weigert J, Schaffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 2006; 79:803-808. This study further elucidates the anti-inflammatory effects of adiponectin. The investigators demonstrate that adiponectin reduces IL-6 expression and increases IL-10 expression in the THP-1 macrophage cell line.
40. Saijo S, Nagata K, Nakano Y, et al. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun 2005; 334:1180-1183.
41. Zhao T, Hou M, Xia M, et al. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol 2005; 238:19-30.
42. Yamamoto K, Kiyohara T, Murayama Y, et al. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005; 54:789-796.
43. Kusminski CM, da Silva NF, Creely SJ, et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab 2007; 92:270-276. This study demonstrates the ability of adipocytes to respond to resistin in a proinflammatory manner. Exposure of freshly isolated mesenteric adipocytes leads to increases in the expression of TLR-2 and activation of JNK1 and JNK2.
44. Creely SJ, McTernan PG, Kusminski CM, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 292:E740-E747. This provides a direct demonstration that adipocytes may participate in the generation of innate immunity responses. Treatment of abdominal subcutaneous preadipocytes with LPS led to increases in TLR-2 and TNFα and activates NF-κB.
45. Muzio M, Polentarutti N, Bosisio D, et al. Toll-like receptor family and signalling pathway. Biochem Soc Trans 2000; 28:563-566.
46. Lin Y, Lee H, Berg AH, et al. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000; 275:24255-24263.
47. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acidinduced insulin resistance. J Clin Invest 2006; 116:3015-3025. Mice lacking TLR-4 (an important mediator of innate immunity) exhibited reduced fatty acid-induced inflammatory responses.
48. Shin HD, Park KS, Park BL, et al. Common promoter polymorphism in monocyte differentiation antigen CD14 is associated with serum triglyceride levels and body mass index in nondiabetic individuals. Diabet Med 2006; 23:72-76. Sequencing of the CD14 gene along with 1.5 kb of upstream sequence revealed a promoter polymorphism that was associated with elevated serum triglyceride levels and body mass index. This is one of the rare pieces of data that suggests the potential of effects of fat mass at the DNA level.
49. Gluckman PD, Hanson MA, Beedle AS. Nongenomic transgenerational inheritance of disease risk. Bioessays 2007; 29:145-154. This very interesting review article is part of a series of mini-reviews in the same issue, discussing the effects of nongenomic 'transgenerational' inheritance that can be attributed to lifestyle.
50. Kaati G, Bygren LO, Edvinsson S. Cardiovascular and diabetes mortality determined by nutrition during parents' and grandparents' slow growth period. Eur J Hum Genet 2002; 10:682-688.
51. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-660.
52. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130:2060-2073.
53. Danese S, Sans M, Spencer D, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2006; 56:855-862.
54. Danese S, Scaldaferri F, Vetrano S, et al. Critical role of the CD40-CD40 ligand pathway in governing mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut 2007; 22 Feb [Epub ahead of print].
55. Baillargeon J, Rose DP. Obesity, adipokines, and prostate cancer [review]. Int J Oncol 2006; 28:737-745.
56. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005; 29:1308-1314.
57. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281:1683-1686.
58. Kitade M, Yoshiji H, Kojima H, et al. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats. Hepatology 2006; 44:983-991. In this study, Zucker rats (which develop spontaneous mutations in the leptin receptor) were used to investigate the effects of leptin in liver fibrosis and hepatocarcinoma-induced angiogenesis. The study showed that lack of leptin signaling is associated with reduced levels of VEGF as well as fibrosis and carcinogenesis in the obese animals when compared to their lean nonmutated littermates.
59. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006; 70:146-157. This describes another study that associated an adipocytokine found increased in obese patients with increased angiogenesis. Here, the investigators demonstrated that resistin increases endothelial cell proliferation and migration in a MAPK-dependent manner. Furthermore, they demonstrated the ability of resistin to induce the formation of capillary-like tube when added to HCAEC cells (human coronary artery endothelial cells) as well as to upregulate the expression of several potent angiogenic factors.
60. Wang Y, Xu LY, Lam KS, et al. Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin. Proteomics 2006; 6:3862-3870. This presents an analysis of human serum proteins and identifies binding partners for adiponectin. Binding of adiponectin to thrombospondin-1 (TSP-1) and α2M (both involved in inflammation and angiogenesis) is verified with the use of co-immunoprecipitation and radioligand competitive-binding assays.
61. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:918-932.
62. Karagiannides I, Kokkotou E, Tansky M, et al. Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric preadipocytes. Proc Natl Acad Sci U S A 2006; 103:5207-5212. The authors describe the first observation that colonic mucosal inflammation signals inflammatory changes in mesenteric fat. This study also showed that human mesenteric preadipocytes possess receptors for the neuropeptide SP (a potent proinflammatory regulator of intestinal inflammation) which can mediate pro-inflammatory responses (such as expression of IL-8) in an NF-κB-dependent manner.
63. Duarte-Rojo A, Lezama-Barreda A, Ramirez-Iglesias MT, et al. Is leptin related to systemic inflammatory response in acute pancreatitis? World J Gastroenterol 2006; 12:4392-4396. This study linked increased adipocity with the severity of pancreatitis.